Building Sustainable Healthcare Systems through Innovation and Entrepreneurship, MIT-King’s College of London Summit, May 22, 2019
What role can innovators and entrepreneurs play in overcoming global health challenges, creating a safer and healthier world, and driving global prosperity?
Join us for an #Innovate4Health Twitter chat on Wednesday, May 15 at 9 a.m. Boston / 2 p.m. London time.
The featured experts are Georgina Flatter (@GeorgieMIT), Research Scientist at the Legatum Center for Development and Entrepreneurship at MIT, and Prashant Jha (@drpjha), Head of Affordable Medical Technologies at the School of Biomedical Engineering & Imaging Sciences at King’s College London. Suranga Chandratillake (@surangac) of Balderton Capital, will be leading the discussion as host. Together, they will discuss how innovators and entrepreneurs around the world are challenging what is possible in healthcare and driving global progress.
Watch Andrew Lo, the economist, hedge fund manager, and finance professor at MIT Sloan, discuss his idea to bring Wall Street-style financial engineering to solving one of the most pressing medical problems of our time: curing cancer and rare diseases. Professor Lo’s proposal—the creation of a “megafund” that invests in early-stage biomedical research and drug development —holds promise for new treatments and medicine to fight cancer and other diseases. Robert Langer, the noted entrepreneur, scientist, and Institute Professor at MIT, also appears on the program to talk about bringing investors on board..
Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management and director of the MIT Laboratory for Financial Engineering.
There is a growing consensus that the “bench-to-bedside” process of translating biomedical research into effective therapeutics is broken. A confluence of factors explains such pessimism but among the most widespread is the sense that the current the drug development business model is flawed. The development of new therapeutics is an expensive, lengthy, and risky process that challenges traditional funding vehicles, which are limited in size, Read More »